☆ 4.5 Review

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches

MABS (2023)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches

Rate this paper

Discover Peeref hubs

Ask a Question. Answer a Question.

Export Citation

Share Paper